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Liver fibrosis occurs as a wound-healing scar response following acute and chronic liver inflammation including alcoholic liver
disease, non-alcoholic steatohepatitis, hepatitis B and C, and autoimmune hepatitis. Myofibroblasts, mainly transdifferentiated
from hepatic stellate cells, are pivotal cell types that produce fibrillar collagen. The activation of inflammatory cells, including
Kupffer cells, is a crucial step for activating hepatic stellate cells. Toll-like receptors (TLRs) are pattern recognition receptors that
sense pathogen-associated molecular patterns (PAMPs), which discriminate the products of microorganisms from the host. TLRs
are expressed on Kupffer cells, endothelial cells, dendritic cells, biliary epithelial cells, hepatic stellate cells, and hepatocytes in the
liver. TLR signaling induces potent innate immune responses in these cell types. The liver is constantly exposed to PAMPs, such as
LPS and bacterial DNA through bacterial translocation because there is a unique anatomical link, the portal vein system between
liver and intestine. Recent evidence demonstrates the role of TLRs in the activation of hepatic immune cells and stellate cells
during liver fibrosis. Moreover, crosstalk between TLR4 signaling and TGF-β signaling in hepatic stellate cells has been reported.
This paper highlights the role of TLR signaling in stellate cell activation and the progression of liver fibrosis.
1. Introduction
Liver fibrosis is a wound healing scar response following
acute and chronic liver diseases including chronic hepatitis B
and C, autoimmune hepatitis, nonalcoholic steatohepatitis,
and alcoholic liver disease [1, 2]. The pathohistological
findings of liver cirrhosis, the endstage of liver fibrosis, show
hepatocellular death, a lobular inflammatory cell infiltrate,
excessive deposition of extracellular matrix (ECM) protein,
and the appearance of regenerative nodules that may result
in liver failure, portal hypertension, and hepatocellular
carcinoma [1, 2]. Thus, wound healing scar response in
the liver represents a harmful response rather than a
beneficial response in liver regeneration. Liver fibrosis is
highly associated with chronic hepatocellular injury and
subsequent inflammatory response that produces inflamma-
tory cytokines and recruits inflammatory leukocytes into the
injured site. This inflammatory circumstance in the liver
drives the activation of hepatic stellate cells (HSCs) through
various fibrogenic mediators including TGF-β and PDGF
[1, 2]. Activated HSCs transdifferentiate into myofiboblasts,
which then produce excessive ECM proteins, including
collagen type I, III, and IV. This leads to an irreversible
collagen deposition, resulting in liver fibrosis [1, 2].
Lipopolysaccharide (LPS, also known as endotoxin)
levels in systemic and portal vein blood are increased
in patients with cirrhosis [3, 4]. LPS is a Gram-negative
bacterial cell wall component that binds to the pattern
recognition receptor, Toll-like receptor (TLR) 4 with its
coreceptors MD-2 and CD14, transmits the signals through
adaptor proteins MyD88, TIRAP, TRIF, and TRAM to
activate the kinases, IRAK1, IRAK4, TAK1, JNK, and IKK.
These intracellular kinases lead to the activation of the
transcription factors NF-κB, AP-1, and interferon regulatory
factors (IRFs) resulting in the induction of potent innate
immune responses [5]. Kupffer cells, resident macrophages
in the liver, are known to respond to LPS through TLR4 to
produce various inflammatory cytokines including TNF-α,
IL-1β, IL-6, IL-12, IL-18, and chemokines in granulomatous
liver disease, ischemia/reperfusion liver injury, nonalcoholic
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steatohepatitis, and alcoholic liver disease [6–8]. HSCs,
central cell types in liver fibrosis, also express high levels
of TLR4 [9, 10]. A unique anatomical link, the portal vein
system between the liver and intestines, may allow for the
exposure of bacterial products, including LPS and bacterial
DNA, to the liver [11]. However, the hepatic immune
response is strictly regulated to avoid a harmful response
in physiological conditions [11, 12]. In addition, sterile
inflammation may provide endogenous TLR ligands for the
activation of danger signals inducing fibrogenic response [7].
This paper summarizes the role of TLR signaling in HSC
activation and liver fibrosis.
2. TLR Signaling in Hepatic Stellate Cells
HSCs are located in the space of Disse in the normal
liver. Quiescent HSCs are primary cell types that store
large amounts of Vitamin A-containing lipid droplets in the
human body [1]. Activated HSCs are the major source of
ECM protein in the fibrotic liver. Following liver injury,
HSCs are activated by various fibrogenic stimuli, including
TGF-β and PDGF, and inflammatory cytokines that are
mainly produced from Kupffer cells [1, 2]. After activa-
tion, HSCs lose Vitamin A-containing lipid droplets and
transdifferentiate into myofibroblasts that highly express α-
smooth muscle actin (SMA). The excessive production and
deposition of ECM proteins cause hepatic fibrosis [2]. We
have demonstrated that activated humanHSCs express TLR4
and its coreceptors MD-2 and CD14 [9]. LPS treatment
induces the strong activation of NF-κB and JNK/AP-1
pathways in activated HSCs. LPS enhances expression of
the adhesion molecules ICAM-1 and VCAM-1 on the cell
surface, and induces the secretion of chemokines, IL-8
and MCP-1 in activated HSCs. LPS-induced IL-8 secretion
is completely blocked by inhibiting NF-κB activation and
partially inhibited by JNK inactivation, indicating the critical
role of NF-κB and JNK in TLR4 signaling of HSCs.
Recently, our study demonstrated that TLR4 upregulates the
expression of various types of chemokine (MCP-1, MIP-
1α, MIP-1β, RANTES, KC, MIP-2, and IP-10) and TLR2,
and it downregulates the expression of bone morphogenetic
protein (BMP) and activin membrane bound inhibitor
(Bambi), a transmembrane suppressor of TGF-β signaling
[10, 13]. Bambi is a type I TGF-β receptor that lacks an
intracellular kinase domain and acts as an inhibitor of
BMP, activin and TGF-β signaling. Overexpression of Bambi
inhibits, while a dominant negative form of Bambi enhances,
TGF-β signaling in HSCs [10]. Thus, TLR4-mediated Bambi
downregulation augments TGF-β signaling in HSCs.
Although the ligands for TLR3 and TLR4 stimulate
HSCs to induce IFN-β production through adaptor TRIF in
macrophages [5], HSCs could produce IFN-β in response
to the ligand for TLR3, but not TLR4, suggesting unique
TLR3/TLR4-TRIF signaling pathways in HSCs, which might
be distinct from those in macrophages [14].
HSCs express TLR2, a receptor for Gram-positive bacte-
rial cell wall components, such as peptidoglycan and lipote-
ichoic acid [5, 15]. HSCs barely respond to TLR2 ligands.
Pretreatment of TNF-α or IL-1β significantly upregulates
TLR2 expression in HSCs. This primes HSCs to increase
NF-κB activation and IL-8 production in response to TLR2
ligands [16]. LPS also upregulates TLR2 expression in
HSCs [10], suggesting that the initiation by inflammatory
mediators such as TNF-α, IL-1β, and LPS might be required
for fulfilling TLR2 signaling in HSCs.
TLR9 that recognizes bacteria-derived, unmethylated
CpG-containing DNA, is expressed in HSCs [17]. Watanabe
et al. has demonstrated that host-derived denatured DNA
from apoptotic hepatocytes induces a differentiation of
HSC via TLR9 [17]. Apoptotic hepatocyte DNA induces
fibrogenic responses with the elevation of mRNA levels of
TGF-β and collagen type I in HSCs. In addition, apop-
totic hepatocyte-derived DNA inhibits PDGF-induced HSC
chemotaxis through TLR9 and MyD88 [17].
3. TLR4 Signaling in Liver Fibrosis
The activation of both HSCs and Kupffer cells that express
TLR4 is associated with the progression of liver fibrosis.
TLR4-mutant mice have less liver inflammation and fibrosis
than TLR4-wild-typemice following bile duct ligation (BDL)
and chronic treatment of carbon tetrachloride (CCl4), or
thioacetamide [10]. Mice deficient in CD14 and LPS-binding
protein also show decreased cholestasis-induced liver fibrosis
[18]. These results suggest a strong contribution of LPS-
TLR4 interaction in the development of liver fibrosis. Indeed,
systemic plasma LPS levels are significantly elevated in
these three mouse models of experimental liver fibrosis
[10, 19, 20], suggesting that intestinal microflora-derived
LPS translocates into the liver through the portal vein
by increased intestinal permeability following liver injury.
We have tested the contribution of intestinal microflora
in liver fibrosis. Mice were orally treated with a cocktail
of nonabsorbable broad-spectrum antibiotics (ampicillin,
neomycin, metronidazole, and vancomycin) for 4 weeks
prior to induction of liver fibrosis [10, 21]. This antibiotic
cocktail successfully reduced plasma LPS levels after BDL,
leading to a significant attenuation of liver inflammation
and fibrosis [10]. Thus, intestinal microflora-derived and
translocated LPS participate in TLR4-mediated liver fibrosis,
most likely due to increased intestinal permeability induced
by intestinal dysbiosis, such as bacterial overgrowth, and
disintegrity in the tight junction of intestinal epithelium.
TLR4 is also activated by endogenous ligands, such as
HMGB1, hyaluronan, and heat shock protein 60 [15, 22, 23].
Currently, we do not have strong evidence that endogenous
TLR4 ligands are involved in liver fibrosis. Further investiga-
tion is needed.
Kupffer cells are well-known targets for TLR4 ligand LPS
and produce various types of inflammatory and fibrogenic
cytokines, which may activate HSCs [6, 7]. Quiescent and
activated HSCs also express TLR4 [9, 10]. The specific roles
of TLR4 in Kupffer cells and HSCs during liver fibrosis were
unknown. To investigate these roles, we generated TLR4-
chimeric mice by using bone marrow (BM) transplantation
(BMT) [10]. Kupffer cells are known as radio-resistant
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cells [24, 25]. Thus, a standard type of BMT with whole
body irradiation insufficiently replaces Kupffer cells with
donor BM-derived cells. To resolve this problem, we have
established a new style of BM-chimera using a combination
of whole body irradiation and BMT with specific deletion
of Kupffer cells by liposomal clodronate injection [10].
These TLR4-chimeric mice have a successful replacement of
endogenous Kupffer cells with donor BM-originated Kupffer
cells, which contain TLR4-mutant BM-derived hematopoi-
etic cells, including Kupffer cells, and TLR4-wild recipient-
originated endogenous liver cells, including hepatocytes and
HSCs. Few hepatocytes induce NF-κB nucleartranslocation
in response to LPS in Kupffer cell-depleted mice, confirming
that hepatocytes barely respond to the ligand for TLR4
compared with nonparenchymal liver cells [10, 26]. Recent
exclusive studies have confirmed that HSCs are not BM
derived [27, 28]. Asmentioned above, Kupffer cells andHSCs
are direct targets of LPS in vitro and in vivo [6, 9, 10].
The specific roles of TLR4 in Kupffer cells and HSCs were
discriminated by this TLR4-chimera system. In this study,
the mice with TLR4-mutant endogenous liver cells exhibited
a significant reduction of liver fibrosis, and the mice with
TLR4-wild endogenous liver cells had a sufficient degree of
fibrosis in the liver after BDL [10]. These findings indicate
that the recipient-originated endogenous liver cells, but not
donor-derived BM cells including Kupffer cells, are crucial
cell types that respond to TLR4 ligands in liver fibrosis.
4. Crosstalk between TLR4 Signaling and
TGF-β Signaling in Stellate Cell Activation
There are at least two roles of TLR4 signaling in HSCs.
First, TLR4-stimulated HSCs produce various chemokines
and express adhesion molecules (ICAM-1, VCAM-1, and
E-selectin) to recruit Kupffer cells and/or circulating
macrophages by the site of HSCs. Indeed, conditioned
medium produced from LPS-treated HSCs increased Kupffer
cell migration and adhesion [10]. Second, the activation of
TLR4 signaling enhances TGF-β signaling in HSCs [10].
HSCs isolated from collagen promoter-driven GFP trans-
genic (Coll-GFP) mice increase GFP intensity when collagen
promoter activity is increased [29]. TGF-β treatment alone
slightly increased collagen promoter activity in quiescent
HSCs whereas LPS pretreatment further increased TGF-β-
induced collagen promoter activity in HSCs. These findings
suggested that TLR4 signaling enhances TGF-β signaling in
HSCs [10]. We then tested the role of Kupffer cells in HSC
activation by co-cultured Coll-GFP HSCs with Kupffer cells.
Coll-GFP HSCs cocultured with Kupffer cells increased GFP
expression, which was further augmented by LPS pretreat-
ment, suggesting that TLR4 signaling enhances Kupffer cell-
mediated HSC activation [10]. Coll-GFP HSCs co-cultured
with TLR4-mutant Kupffer cells express a similar level of
GFP expression to the HSCs co-cultured with wild-type
Kupffer cells after LPS stimulation. Thus, TLR4 on Kupffer
cells has aminor role for TLR4-mediatedHSC activation, but
Kupffer cells are required forHSC activation as the important
source of TGF-β because HSC activation was completely
abolished by treatment with a TGF-β inhibitor in co-culture
of Kupffer cells and HSCs.
Comprehensive microarray analysis demonstrated that
Bambi, a transmembrane TGF-β receptor inhibitor, was
downregulated in HSCs after LPS stimulation, whereas other
TGF-β signaling associated genes (TGF-β receptor, Smad
family, SNoN, Ski, and Sara) were unchanged [10, 13].
Quiescent HSCs, but not Kupffer cells and hepatocytes,
express high levels of Bambi in the liver. Importantly,
Bambi expression is suppressed in in vivo activated HSCs
isolated from mice after BDL or chronic CCl4 treatment
whereas HSCs isolated from bile duct ligated-TLR4-mutant
mice have unchanged levels of Bambi expression [10].
We suggest that high levels of Bambi expression restrict
TGF-β signaling in HSCs of normal livers. Upon TLR4
stimulation Bambi expression is quickly decreased. Then,
TGF-β signaling becomes free from the restriction by Bambi
to promote fibrogenic response. Interestingly, HSCs activated
in culture do not downregulate Bambi expression. Thus,
Bambi downregulation is an important feature of HSC acti-
vation in vivo. One study clearly demonstrated that human
Bambi inhibits TGF-β-induced Smad3 phosphorylation,
and silencing endogenous Bambi enhances TGF-β reporter
activity [30]. The study further revealed that Bambi interacts
with Smad7, interfering with the complex composed of
type I and type II TGF-β receptors, and Smad3, resulting
in inhibiting TGF-β signaling. In addition, Harada et al.
demonstrated that Bambi expression in biliary epithelial cells
is downregulated during epithelial-mesenchymal transition
(EMT), suggesting an additional role of Bambi as a marker
for EMT [31].
TLR4 signaling activates NF-κB and JNK/AP-1 pathways
through MyD88 and TRIF [15]. TLR4-mediated downreg-
ulation of Bambi expression requires the activation of NF-
κB and partially JNK through MyD88, but not TRIF, in
HSCs. Indeed, Bambi expression was downregulated in WT
and TRIF−/− HSCs, but not in MyD88−/−, NF-κB, or JNK
inactivated HSCs after LPS stimulation (E.S. unpublished
observation) [10]. Similarly, MyD88−/−, but not TRIF−/−,
mice demonstrated reduced fibrogenic gene expression at the
early phase after BDL, whereas both MyD88−/− and TRIF−/−
mice had reduced liver fibrosis at the late phase of liver
fibrosis [10]. These findings suggest that MyD88 is crucial
for the Bambi-regulated liver fibrosis, whereas TRIF regulates
fibrogenic responses independently of Bambi, at least at the
chronic stage. Taken together, TLR4 signaling is crucial in the
activation of HSCs during liver fibrosis. Intestinal microflora
is a major source of LPS as a ligand for TLR4 in liver
fibrosis. TLR4 signaling in HSCs enhances the recruitment of
inflammatory cells and downregulates Bambi for fibrogenic
response Figure 1.
5. TLR4 Polymorphism, HSCs, and
Liver Fibrosis
A recent genecentric functional genome scan in patients
with chronic hepatitis C virus has identified seven single
nucleotide polymorphisms (SNPs) that may predict the risk
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Figure 1: TLR4 signaling enhances TGF-β signaling in hepatic stellate cells. Upon liver injury, intestinal permeability is increased due to
the intestinal dysbiosis and tight junction disintegrity, which allows microflora-derived LPS into the portal vein. This LPS stimulates TLR4
on hepatic stellate cells (HSCs). Quiescent HSCs express high levels of Bambi which restricts TGF-β signaling. TLR4 stimulation leads to
the production of various chemokines (MCP-1, MIP-1β, and RANTES) in HSCs, recruiting Kupffer cells through their CCR1 and CCR2.
Recruited Kupffer cells produce TGF-β which binds to TGF-β receptor type I in HSCs. Simultaneously, TLR4 signaling downregulates Bambi
expression through MyD88 and NF-κB in HSCs. HSCs become free from restricted TGF-β signaling by the downregulation of Bambi, which
eventually induces HSC activation.
of developing liver cirrhosis [32, 33]. Among these seven
SNPs, a TLR4 T399I SNP is the second most predictive in
protecting the progression of liver cirrhosis. TLR4 D299G
is another TLR4 SNP. These two SNPs are associated with
a blunted response to LPS [34]. These findings confirmed
the relevance of TLR4 in a large group of patients with
liver fibrosis. Based on this study, Guo et al. examined the
response of HSCs with TLR4 D299G and T3991 SNPs to
LPS. TLR4 D299G and/or T3991 SNPs were reconstituted
into a human stellate cell line, LX-2 cells, and immortalized
TLR4−/− mouse HSCs (TLR4−/−mHSC) [35]. LX-2 cells or
TLR4−/−mHSCs expressing either the one or both SNPs
displayed a marked reduction of NF-κB activity and cytokine
production (MCP-1 and IL-6) and unchanged Bambi expres-
sion [35]. The TLR4 SNPs inhibited HSC growth and
enhanced spontaneous HSC apoptosis [35]. These findings
demonstrated the mechanistic function of the two TLR4
SNPs in HSC activation and the risk of fibrosis progression.
6. TLR3 in Liver Fibrosis
TLR3 recognizes double stranded RNA, such as polyinosinic-
polycytidylic acid (poly I:C), to induce a potent innate
immune response that includes the production of inter-
feron type I and type II. TLR3 ligand poly I:C treat-
ment attenuates liver fibrosis induced by the treatment of
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3,5-diethoxycarbonyl-1,4-dehydrocollidine (DDC) diet and
CCl4 [36]. This fibrosis reduction by poly I:C is NK cell
dependent and IFN-γ dependent. NK cells stimulated with
poly I:C induce the cytotoxicity to activated HSCs, but not
quiescent HSCs. Poly I:C directly, and indirectly through
IFN-γ, enhances TRAIL expression in NK cells, and this
increases the cytotoxicity of NK cells against activated HSCs,
resulting in the suppression of liver fibrosis. The research
group further demonstrated that poly I:C-dependent NK
cell-dependent suppression of liver fibrosis is inhibited in
ethanol-treated animals [37]. These findings suggest that the
reduction of TLR3-mediated NK cell-dependent HSC killing
is one of the mechanisms underlying the enhancement of
liver fibrosis in alcoholic liver disease.
7. TLR9 in Liver Fibrosis
TLR9 recognizes bacteria-derived unmethylated CpG rich
DNA [5]. A recent report from our group clearly suggests
that liver fibrosis progression is associated with intestinal
microflora-derived products and their translocation [10].
Previous studies have shown that patients and animals with
cirrhosis have increased bacterial DNA levels in their plasma
and ascites [38, 39]. On the other hand, Watanabe et al.
demonstrated that denatured host origin DNA from dying
hepatocytes stimulates HSCs through TLR9 in liver fibrosis.
TLR9−/− mice showed a reduction of liver fibrosis after BDL
and chronic CCl4 treatment [17, 40]. These findings suggest
that both bacterial DNA and host denatured DNA derived
from dying cells participate in the progression of liver fibrosis
as a ligand for TLR9.
Recently, Connolly et al. have demonstrated the contri-
bution of TLR9 and CD11c-expressing cells to liver fibrosis
[41]. CD11c is expressed on dendritic cells (DCs) and some
monocytes and macrophages [42]. They used the model of
liver fibrosis induced by thioacetamide plus leptin treatment
as a similar pathophysiology to CCl4 models. Depletion of
CD11c-expressing cells using CD11c-DTR mice significantly
reduced liver fibrosis, suggesting the importance of CD11c-
expressing non-parenchymal liver cells in the progression of
liver fibrosis [41]. CD11c-expressing cells from fibrotic liver
increased the capacity to produce TNF-α, IL-6, and various
chemokines, which were further increased by TLR9 ligand
stimulation in CD11c-expressing cells of fibrotic livers, but
not of normal livers. This increased sensitivity of fibrotic
liver CD11c-positive cells to TLR ligands was induced only
by the ligand for TLR9, not TLR3, TLR4, or TLR5. CpG-
DNA-primed fibrotic liver CD11c-positive cells increased
NK cell cytotoxicity and cytokine production, including
IFN-γ in a TNF-α dependent manner [41]. CpG-DNA-
primed fibrotic liver CD11c-positive cells induced HSC
proliferation and production of inflammatory mediators,
such as IL-1α, IL-6, and MCP-1. This study demonstrated
the important features of TLR9 and DCs in liver fibrosis
using CD11c-depleted mice. However, the studies for DCs
in liver fibrosis are still incomplete. Further studies are
needed to clarify the role of DCs in the progression of liver
fibrosis.
8. TAK1 in Liver Fibrosis
TAK1 is a MAP3K which is activated by the signaling of
TLRs, IL-1 receptor, TNF receptor, and TGF-β receptor
[43, 44]. TAK1 is an upstream kinase of both IKK/NF-κB
and JNK/AP-1 pathways [15]. The NF-κB pathway regulates
the expression of antiapoptotic genes, such as Bcl-2, Bcl-
xL, A20, iNOS, c-FLIP, IAPs, and TRAF family molecules,
to block death receptor-mediated or mitochondria-mediated
hepatocytes death [45]. NF-κB also prevents prolonged
JNK activation. Prolonged JNK activation induces phos-
phorylation of the E3 ligase Itch and subsequent ubiq-
uitination and degradation of caspase-8 inhibitor c-FLIP,
which accelerates hepatocyte apoptosis [46]. Thus, NF-κB
protects hepatocytes from apoptosis whereas JNK promotes
apoptosis. Therefore, we could not predict whether TAK1
tends to induce or protect from hepatocyte apoptosis.
As expected, neither NF-κB nor JNK activation following
TNF-α stimulation occurred in TAK1−/− hepatocytes [47].
Surprisingly, TAK1−/− hepatocytes increased the sensitivity
to TNF-α-induced cell death. More surprisingly, sponta-
neous hepatocyte death occurred in hepatocyte specific
TAK1−/− mice [47]. These mice display spontaneous liver
injury, inflammation, and fibrosis at the age of one month
and develop hepatocellular carcinoma at the age of nine
months [47, 48]. These results suggest that spontaneous
persistent hepatocyte death occurs in hepatocyte specific
TAK1−/− mice, and these dying hepatocytes release alarmins
which stimulate both Kupffer cells and HSCs, resulting in
liver inflammation and fibrosis Figure 2. These findings are
evidence that liver fibrosis and carcinogenesis are associated
with persistent hepatocyte injury and inflammation without
any carcinogens. Hepatocyte specific TAK1−/− mice will be
great animal models for addressing the role of the interplay
between fibrosis and hepatocellular carcinoma.
9. Conclusion
While patients with mild to moderate liver fibrosis may
not show clinical symptoms, liver cirrhosis is a major
cause of morbidity and mortality. Recent advanced studies
demonstrated the strong evidence of the role of TLR
signaling in liver fibrosis. A number of issues concerning
the role of TLRs for HSC activation and liver fibrosis still
need to be addressed. First, although we have shown the
evidence that intestinal microflora promotes liver fibro-
genesis due to bacterial translocation, we still need to
address the mechanism of bacterial translocation in liver
fibrosis, which includes changes in microbiome composition
and disintegrity of intestinal tight junction. Second, the
studies for the endogenous TLR ligands which promote
HSC activation have not been completed. Very recently,
mitochondrial DNA has been reported as an endogenous
TLR9 ligand [49], which might be an endogenous ligand to
activate HSCs. Third, we need to address the mechanism
by which TLR signaling regulates Bambi expression and
by which Bambi regulates HSC activation. The research on
TLRs and HSCs in liver fibrosis has just been started. The
future basic and translational studies will uncover additional
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Figure 2: Ablation of TAK1 in hepatocytes induces spontaneous liver injury, inflammation, fibrosis, and cancer. Spontaneous hepatocyte
death occurs in hepatocyte specific TAK1-deficient mice followed by the release of damage-associated molecular patterns (DAMPs) which
stimulate Kupffer cells to produce TNF-α. This TNF-α further induces cell death in TAK1-deficient hepatocytes lacking activation of NF-κB
and JNK. TNF-α, IL-1β, and IL-6 released from Kupffer cells cause liver inflammation. Kupffer cell-derived TGF-β stimulates hepatic stellate
cells resulting in fibrogenesis. The persistent hepatocyte death and uncontrolled compensatory proliferation in the livers of hepatocyte
specific TAK1-deficient mice induce the reactivation of onco-fetal liver genes that are associated with the initiation of hepatic carcinogenesis.
clinical relevance of TLRs and their related signaling in
liver fibrosis. Clinically, hepatocellular carcinoma is strongly
associated with liver fibrosis and cirrhosis. However, it is
still unknown whether severe liver fibrosis promotes the
initiation and/or progression of hepatocellular carcinoma.
We wish to open this mysterious door in future studies using
hepatocyte specific TAK1−/− mice.
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